Serdar Yavuzyigitoglu1, Anna E Koopmans1, Robert M Verdijk2, Jolanda Vaarwater1, Bert Eussen3, Alice van Bodegom1, Dion Paridaens4, Emine Kiliç5, Annelies de Klein6. 1. Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Centre, Rotterdam, The Netherlands. 2. Department of Pathology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 3. Department of Clinical Genetics, Erasmus University Medical Centre, Rotterdam, The Netherlands. 4. The Rotterdam Eye Hospital, Rotterdam, The Netherlands. 5. Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 6. Department of Clinical Genetics, Erasmus University Medical Centre, Rotterdam, The Netherlands. Electronic address: a.deklein@erasmusmc.nl.
Abstract
PURPOSE: To investigate the prevalence and prognostic value of SF3B1 and EIF1AX mutations in uveal melanoma (UM) patients. DESIGN: Case series. PARTICIPANTS: Cohort of 151 patients diagnosed with and treated for UM. METHODS: SF3B1 and EIF1AX mutations in primary tumors were investigated using whole-exome sequencing (n = 25) and Sanger sequencing (n = 151). For the detection of BAP1 mutations, a previously reported cohort of 90 patients was extended using BAP1 sequencing or immunohistochemistry. MAIN OUTCOME MEASURES: The status of SF3B1, EIF1AX, and BAP1 in tumors of patients were correlated to clinical, histopathologic, and genetic parameters. Survival analyses were performed for patients whose tumors had SF3B1, EIF1AX, and BAP1 mutations. RESULTS: Patients with tumors harboring EIF1AX mutations rarely demonstrated metastases (2 of 28 patients) and overall had a longer disease-free survival (DFS; 190.1 vs. 100.2 months; P < 0.001). Within the patient group with disomy 3, UM patients with an SF3B1 mutation had an increased metastatic risk compared with those without an SF3B1 mutation (DFS, 132.8 vs. 174.4 months; P = 0.008). Patients with such a mutation were more prone to demonstrate late metastases (median, 8.2 years; range, 23-145 months). Patients with UM and loss of BAP1 expression had a significantly decreased survival (DFS, 69.0 vs. 147.9 months; P < 0.001). CONCLUSIONS: According to our data, patients with UM can be classified into 3 groups, of which EIF1AX-mutated tumors and tumors without BAP1, SF3B1, or EIF1AX mutations are associated with prolonged survival and low metastatic risk, SF3B1-mutated tumors are associated with late metastasis, and tumors with an aberrant BAP1 are associated with an early metastatic risk and rapid decline in patient DFS.
PURPOSE: To investigate the prevalence and prognostic value of SF3B1 and EIF1AX mutations in uveal melanoma (UM) patients. DESIGN: Case series. PARTICIPANTS: Cohort of 151 patients diagnosed with and treated for UM. METHODS:SF3B1 and EIF1AX mutations in primary tumors were investigated using whole-exome sequencing (n = 25) and Sanger sequencing (n = 151). For the detection of BAP1 mutations, a previously reported cohort of 90 patients was extended using BAP1 sequencing or immunohistochemistry. MAIN OUTCOME MEASURES: The status of SF3B1, EIF1AX, and BAP1 in tumors of patients were correlated to clinical, histopathologic, and genetic parameters. Survival analyses were performed for patients whose tumors had SF3B1, EIF1AX, and BAP1 mutations. RESULTS:Patients with tumors harboring EIF1AX mutations rarely demonstrated metastases (2 of 28 patients) and overall had a longer disease-free survival (DFS; 190.1 vs. 100.2 months; P < 0.001). Within the patient group with disomy 3, UM patients with an SF3B1 mutation had an increased metastatic risk compared with those without an SF3B1 mutation (DFS, 132.8 vs. 174.4 months; P = 0.008). Patients with such a mutation were more prone to demonstrate late metastases (median, 8.2 years; range, 23-145 months). Patients with UM and loss of BAP1 expression had a significantly decreased survival (DFS, 69.0 vs. 147.9 months; P < 0.001). CONCLUSIONS: According to our data, patients with UM can be classified into 3 groups, of which EIF1AX-mutated tumors and tumors without BAP1, SF3B1, or EIF1AX mutations are associated with prolonged survival and low metastatic risk, SF3B1-mutated tumors are associated with late metastasis, and tumors with an aberrant BAP1 are associated with an early metastatic risk and rapid decline in patient DFS.
Authors: Duncan E Berry; Amy C Schefler; Michael I Seider; Miguel Materin; Sandra Stinnett; Prithvi Mruthyunjaya Journal: Retina Date: 2018-11-08 Impact factor: 4.256
Authors: Beryl Royer-Bertrand; Matteo Torsello; Donata Rimoldi; Ikram El Zaoui; Katarina Cisarova; Rosanna Pescini-Gobert; Franck Raynaud; Leonidas Zografos; Ann Schalenbourg; Daniel Speiser; Michael Nicolas; Laureen Vallat; Robert Klein; Serge Leyvraz; Giovanni Ciriello; Nicolò Riggi; Alexandre P Moulin; Carlo Rivolta Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris Journal: J Clin Invest Date: 2019-10-01 Impact factor: 14.808
Authors: Kyra N Smit; Natasha M van Poppelen; Jolanda Vaarwater; Robert Verdijk; Ronald van Marion; Helen Kalirai; Sarah E Coupland; Sophie Thornton; Neil Farquhar; Hendrikus-Jan Dubbink; Dion Paridaens; Annelies de Klein; Emine Kiliç Journal: Mod Pathol Date: 2018-01-12 Impact factor: 7.842
Authors: Eszter Szalai; Yi Jiang; Natasha M van Poppelen; Martine J Jager; Annelies de Klein; Emine Kilic; Hans E Grossniklaus Journal: JAMA Ophthalmol Date: 2018-10-01 Impact factor: 7.389
Authors: Anneke Kievit; Federico Tessadori; Hannie Douben; Ingrid Jordens; Madelon Maurice; Jeannette Hoogeboom; Raoul Hennekam; Sheela Nampoothiri; Hülya Kayserili; Marco Castori; Margo Whiteford; Connie Motter; Catherine Melver; Michael Cunningham; Anne Hing; Nancy M Kokitsu-Nakata; Siulan Vendramini-Pittoli; Antonio Richieri-Costa; Annette F Baas; Corstiaan C Breugem; Karen Duran; Maarten Massink; Patrick W B Derksen; Wilfred F J van IJcken; Leontine van Unen; Fernando Santos-Simarro; Pablo Lapunzina; Vera L Gil-da Silva Lopes; Elaine Lustosa-Mendes; Max Krall; Anne Slavotinek; Victor Martinez-Glez; Jeroen Bakkers; Koen L I van Gassen; Annelies de Klein; Marie-José H van den Boogaard; Gijs van Haaften Journal: Eur J Hum Genet Date: 2018-01-18 Impact factor: 4.246
Authors: A Gordon Robertson; Juliann Shih; Christina Yau; Ewan A Gibb; Junna Oba; Karen L Mungall; Julian M Hess; Vladislav Uzunangelov; Vonn Walter; Ludmila Danilova; Tara M Lichtenberg; Melanie Kucherlapati; Patrick K Kimes; Ming Tang; Alexander Penson; Ozgun Babur; Rehan Akbani; Christopher A Bristow; Katherine A Hoadley; Lisa Iype; Matthew T Chang; Andrew D Cherniack; Christopher Benz; Gordon B Mills; Roel G W Verhaak; Klaus G Griewank; Ina Felau; Jean C Zenklusen; Jeffrey E Gershenwald; Lynn Schoenfield; Alexander J Lazar; Mohamed H Abdel-Rahman; Sergio Roman-Roman; Marc-Henri Stern; Colleen M Cebulla; Michelle D Williams; Martine J Jager; Sarah E Coupland; Bita Esmaeli; Cyriac Kandoth; Scott E Woodman Journal: Cancer Cell Date: 2017-08-14 Impact factor: 31.743